The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Patients with CKD who use antiresorptive drugs for tumor-related disorders or oral corticosteroids may be at increased risk for osteonecrosis of the jaw.

Novo Nordisk's GLP-1 receptor agonist semaglutide ... MASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects between 6 million to 8 million people in the US alone and for some ...

Novo Nordisk ... on Novo Nordisk's obesity and diabetes business – which is also seeing heavy investment in manufacturing – the company has a longstanding interest in the rare disease category.